All News

The clinical trial expansion is part of efforts to detect potential adverse effects in children, such as heart inflammation problems.

According to the investigators, this discrepancy remains even if the individual reported symptoms of heart failure during a routine outpatient health care appointment within the past 6 months.

Theresa McArdle, MBA, senior brand marketing manager at Pharmavite, to discuss new survey data that showed a decline in self-care among pharmacists coming out of the COVID-19 pandemic.

Ken Perez, MBA, vice president of healthcare policy and government affairs at Omnicell, discussed the pandemic's impact on the legislative push to grant pharmacists provider status for Medicare Part B.

The combination of pembrolizumab and chemotherapy marks the first immunotherapy regimen approved for patients with high-risk early-stage triple-negative breast cancer.

Pharmacy Times interviewed Craig Freyer, PharmD, BCOP, and Andrew Lin, PharmD, BCOP, to discuss the updates in the prevention and treatment of cytokine release syndrome and neurologic toxicities for patients with multiple myeloma.

Evkeeza has been approved as an adjunct to other low-density lipoprotein cholesterol-lowering therapies to treat patients 12 years and older with homozygous familial hypercholesterolemia.

According to the investigators, treatment with ruxolitinib resulted in a significant improvement in ORR after 24 weeks, with an ORR of 49.7% in the ruxolitinib arm compared to 25.6% in the best available therapy arm.

Two of the studies also found that patients with COVID-19 who received remdesivir had a significantly increased chance of discharge from the hospital by day 28.

One dose of AstraZeneca’s COVID-19 vaccine (Vaxzevria) was 82% effective against hospitalization or death caused by either the Beta or Gamma variants of the SARS-CoV-2 virus, according to data from the Canadian Immunization Research Network, currently published as a pre-print.

The research team noted that although HCL has a good prognosis for the majority of patients, a small population will develop variants of the disease do not respond well to existing FDA-approved therapies or cannot tolerate the adverse effects of established therapies.

Heart failure outcomes improve with optimal iron levels.

APhA offers intensive certificate course on integrating education and management into practice.

Zoster vaccine recombinant, adjuvanted has been approved by the FDA for the prevention of herpes zoster in adults 18 years of age and older who are, or will be, at an increased risk of shingles because of immunodeficiency or immunosuppression.

Joint statement released supporting belief that COVID-19 vaccines are the logical fulfillment of the ethical obligation of all health care workers to put their patients first.

According to a press release from Saniona, Tesomet is the first and only investigational treatment for HO to receive orphan drug designation.

How would you respond to these patients' questions?

Axicabtagene ciloleucel (Yescarta) received accelerated FDA approval on March 5, 2021, for the treatment of adult patients with relapsed or refractory FL after 2 or more lines of systemic therapy.

This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.

Ten quiz questions to assess your knowledge on common diabetes treatments.

Aldosterone blockers, such as spironolactone and eplerenone, can cause hyperkalemia.

Follow these 6 tips for making the move to a nontraditional career or role within the profession.

How would you respond to these patients' concerns?

Ken Perez, MBA, vice president of healthcare policy and government affairs at Omnicell, discussed the changes that would take place if pharmacists were granted provider status for Medicare Part B.

Consider key elements of acute bacterial skin and skin structure infection to help patients manage this broad range of diseases.

A new survey conducted by The Harris Poll on behalf of the Samueli Foundation found that 29% of Americans are taking more supplements compared with before the COVID-19 pandemic, bringing the nationwide percentage of supplement-takers to 76%.

The findings showed that on average, college students with ADHD received grades that were half a grade level below their peers in all 4 years.

The FDA has granted Orphan Drug Designation (ODD) to alrizomadlin (APG-115, Ascentage Pharma) for the treatment of stage IIB-IV melanoma.